Fuente: FierceBiotech Sanofi is replacing CEO Paul Hudson with Merck KGaA leader Belén Garijo, M.D., Ph.D., after a series of R&D setbacks at the French pharma. Hudson will end his six-year run at Sanofi’s helm Feb. 17, at which point Olivier Charmeil, executive vice president of general medicines, will step in as interim CEO until Garijo arrives April 29.